Merck spends $10 billion for Verona, gaining access to its COPD medication
The deal gives Merck access to Verona Pharma's new chronic obstructive pulmonary disease medication Ohtuvayre. U.S. regulators approved the inhaled medication more than a year ago to treat chronic obstructive pulmonary disease, or COPD, in adults.
'Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardiopulmonary diseases while delivering near- and long-term growth as well as value for shareholders,' Merck & Co. Inc. Chairman and CEO Robert Davis said in a statement.
Verona CEO David Zaccardelli added that Merck's commercial reach can help Ohtuvayre reach more COPD patients.
COPD is a progressive disease that can cause shortness of breath, coughing and other problems that make it hard to breathe, according to the National Institutes of Health. It is caused by damage to the airways or other parts of the lung and affects more than 14 million adults in the United States.
Ohtuvayre was launched last August as the first commercial product for London-based Verona Pharma. The drug also is being studied as a possible treatment for another chronic respiratory problem that gets worse over time: non-cystic fibrosis bronchiectasis.
Merck plans to pay $107 for each Verona Pharma American Depository Share, which represents eight of the company's ordinary shares.
The deal announced Wednesday has been approved by the boards of both companies and is expected to close in the fourth quarter. But it still needs Verona Pharma shareholder approval and sanction by the High Court of Justice of England and Wales.
Shares of Rahway, New Jersey-based Merck climbed 25 cents to $81.63 before markets opened Wednesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
22 minutes ago
- CNBC
Oil major BP posts second-quarter profit beat despite annual drop
Britain's BP on Tuesday posted stronger-than-expected second-quarter profit, following a period of heightened volatility for global oil and gas prices. The struggling energy major reported underlying replacement cost profit, used as a proxy for net profit, of $2.35 billion for the three months through June. That beat analyst expectations of $1.81 billion, according to an LSEG-compiled consensus. BP's net profit came in at $2.76 billion over the second quarter of last year and $1.38 billion in the first three months of 2025. The results come as BP continues to try to rebuild investor confidence following a protracted period of underperformance relative to its industry peers. The London-listed company on Monday announced its largest oil and gas discovery in 25 years off the coast of Brazil, reflecting a potentially significant boost as it continues to double down on hydrocarbons. BP has recently been the subject of intense takeover speculation, prompting domestic rival Shell to say in late June that it had "no intention" of making an offer. Shares of the company are up around 3.3% year-to-date.
Yahoo
an hour ago
- Yahoo
Helios Towers First Half 2025 Earnings: EPS: US$0.029 (vs US$0.02 loss in 1H 2024)
Explore Helios Towers's Fair Values from the Community and select yours Helios Towers (LON:HTWS) First Half 2025 Results Key Financial Results Revenue: US$418.3m (up 7.3% from 1H 2024). Net income: US$30.4m (up from US$20.8m loss in 1H 2024). Profit margin: 7.3% (up from net loss in 1H 2024). EPS: US$0.029 (up from US$0.02 loss in 1H 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Helios Towers Earnings Insights Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Telecom industry in Europe. Performance of the market in the United Kingdom. The company's shares are down 1.8% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 2 warning signs for Helios Towers you should be aware of, and 1 of them can't be ignored. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Those who invested in Castings (LON:CGS) five years ago are up 9.0%
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term Castings P.L.C. (LON:CGS) shareholders for doubting their decision to hold, with the stock down 23% over a half decade. On top of that, the share price is down 5.9% in the last week. However, this move may have been influenced by the broader market, which fell 2.6% in that time. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years over which the share price declined, Castings' earnings per share (EPS) dropped by 16% each year. The share price decline of 5% per year isn't as bad as the EPS decline. So investors might expect EPS to bounce back -- or they may have previously foreseen the EPS decline. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Castings, it has a TSR of 9.0% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments! A Different Perspective Investors in Castings had a tough year, with a total loss of 16% (including dividends), against a market gain of about 22%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 1.7%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Castings is showing 2 warning signs in our investment analysis , and 1 of those is potentially serious... We will like Castings better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
